Dual Antiplatelet Therapy

Among patients who underwent PCI with a drug-eluting stent, switching from dual antiplatelet therapy to ticagrelor monotherapy at 3 months was similarly beneficial in men and women, according to new data from the TWILIGHT trial.

Among patients at high ischemic and bleeding risk, longer duration of dual antiplatelet therapy after PCI for ACS was associated with lower risk for adverse events at 30 months vs. shorter duration DAPT, a speaker reported.

Long-term risk for coronary revascularization, MI and death persisted up to 5 years after premature discontinuation of dual antiplatelet therapy among patients who underwent PCI, researchers reported.

Among patients who underwent PCI with a sirolimus-eluting stent, short-term and long-term dual antiplatelet therapy conferred similar rates of target vessel failure, researchers reported.

Outcomes with 14 days of dual antiplatelet therapy after PCI with a nanocoated stent (Cobra PzF, CeloNova Biosciences) compared with 3- to 6-month DAPT after PCI with a drug-eluting stent.

One month of dual antiplatelet therapy followed by aspirin monotherapy after PCI with a polymer-free drug-coated stent was noninferior to 6 to 12 months of DAPT after PCI with a contemporary drug-eluting stent, researchers reported.

Saphenous vein graft occlusion, graft failure and bleeding with aspirin plus ticagrelor (Brilinta, AstraZeneca) after CABG compared with aspirin alone.

Net adverse clinical events in patients who underwent PCI for ACS according to aspirin-prasugrel (Effient, Daiichi Sankyo/Eli Lilly) strategy.

Among patients on oral anticoagulation, those who had dual antiplatelet therapy for 14 days after PCI with a nanocoated stent had worse outcomes compared with those assigned 3-to-6-month DAPT after PCI with a drug-eluting stent.

Dual antiplatelet therapy for 1 month or 3 months was noninferior to a 12-month duration with regard to all-cause mortality and MI in patients with high bleeding risk undergoing PCI, researchers found.